Sign up for a new account.
And get access to
The latest T1D content
Research that matters
Our daily questions
Sign up by entering your info below.
Reset Your Password
We will email you instructions to reset your
The COVID-19 pandemic has put immense pressure on both individuals with T1D, and the organizations who provide them with vital supplies and medications. While there’s no doubt that people with T1D face a more uncertain and risk-filled future as we navigate quarantine and social distancing, there have been some promising steps from several sides that have eased burdens and continue to help those who are struggling.
One of the most vital elements of care and population health for those with T1D is meeting a continued need for medical supplies and vital prescriptions such as insulin, injection devices, and continuous glucose monitors (CGMs_. To this end, many of the prominent pharmaceutical and device companies in the T1D sector have taken extraordinary measures to help their customers and clients.
In response to the crisis, Dexcom, a technological leader in continuous glucose monitoring (CGM)systems and diabetes care, has announced welcome news for people with T1D: A new patient assistance program to aid current U.S. customers who have lost insurance due to the COVID-19 pandemic.
The program will offer eligible customers two (2) ninety 90-day supply shipments, with each dispatch including one transmitter and three boxes of sensors at just $45 per 90-day shipment.
“As unemployment rates continue to rise, we want to help our customers who rely on Dexcom CGM systems to manage their diabetes but have lost insurance coverage due to the impact of the COVID-19 pandemic,” said Kevin Sayer, chairman, president, and CEO of Dexcom. “Access to Dexcom CGM systems has never been more important than it is during this pandemic, and we are committed to taking care of our customers as best as we can during these challenging and uncertain times.”
The Dexcom COVID-19 patient assistance program will be available to current U.S. customers who have lost insurance coverage as a result of the COVID-19 pandemic. Customers that are eligible for coverage of their Dexcom CGM systems under a federal or state government program (such as Medicare, Medicaid, or VA benefits) are not eligible to participate in this program. The program will launch in the next several weeks and will be available for the duration of the COVID-19 pandemic in the United States.
For the latest information about the patient assistance program, customers can visit dexcom.com/assistance.
For more information and resources about coping with T1D through the COVID-19 pandemic, please check out our Weekly Roundup of T1D resources on Glu.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Join our mailing list for more about T1D
- T1DX-QI Learning Sessions: Promoting Health Equity in T1D Careby Hope WarshawJanuary 18, 2022
- T1DX-QI Learning Sessions Overview – 2021by Jewels DoskiczJanuary 11, 2022
- Top Questions of the Day – December 2021by Sarah TackettJanuary 4, 2022
- T1D Exchange Top Research Highlights of 2021by Sarah TackettDecember 30, 2021
- New Study Results: Perspectives on Video Visits for T1D Careby Sarah TackettDecember 20, 2021